Dr. Cataland is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
460 W 10th Ave
Columbus, OH 43210Phone+1 614-293-8619Fax+1 614-293-6420
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
Ohio State University HospitalResidency, Internal Medicine, 1994 - 1997- Ohio State University College of MedicineClass of 1994
Certifications & Licensure
OH State Medical License 1995 - 2025
IL State Medical License 1997 - 2002- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Start of enrollment: 2007 Nov 01
- A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura Start of enrollment: 2021 Apr 14
Roles: Principal Investigator
- A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Start of enrollment: 2023 Mar 21
Roles: Principal Investigator
Publications & Presentations
PubMed
- 218 citationsTerminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label TrialFadi Fakhouri, Maryvonne Hourmant, Josep M. Campistol, Spero R. Cataland, Mario Espinosa
American Journal of Kidney Diseases. 2016-07-01 - 61 citationsNone of the above: thrombotic microangiopathy beyond TTP and HUSCamila Masias, Sumithira Vasu, Spero R. Cataland
Blood. 2017-05-25 - 519 citationsCaplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl
The New England Journal of Medicine. 2019-01-09
Journal Articles
- The Role of ADAMTS13 Testing in the Diagnosis and Management of Thrombotic Microangiopathies and ThrombosisSpero R Cataland, Camila Masias, Blood
Abstracts/Posters
- Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression RegimenSpero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic PurpuraSpero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative StudySpero Cataland, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Adult Clinical Non-Malignant Hematology61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Cost Is the Main Hurdle to Broad Use of Caplacizumab for TTPDecember 7th, 2020
Ultomiris Receives Approval for Atypical Hemolytic Uremic SyndromeOctober 22nd, 2019
Alexion Receives FDA Approval for ULTOMIRIS® (Ravulizumab-Cwvz) for Atypical Hemolytic Uremic Syndrome (aHUS)October 18th, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
